Article

ASCO Praises Congressional Action on SGR

Following last night's vote by the Senate to repeal the SGR bill, the largest society of oncologists praised the action by Congress to end this Medicare reimbursement controversy.

“Today’s courageous vote by the U.S. Senate to finally end the Sustainable Growth Rate formula is a vote for the millions of patients with cancer who depend on Medicare to help them fight their disease. With Congress passing this historic legislation to finally end the 13-year SGR roller coaster ride, Medicare beneficiaries and their physicians can breathe easier knowing that they will no longer face the perennial threat of payment cuts that risk disruption of care and cause anxiety among patients.

We praise the 92 Senators for voting “yes” on The Medicare Access and CHIP Reauthorization Act of 2015 (H.R.2) and for joining the 392 House members who voted earlier to support this long-awaited legislation. The Congressional bipartisan, bicameral leadership that forged this much-anticipated resolution has taken an important step to restore stability and confidence in Medicare.

The American Society of Clinical Oncology looks forward to working with policymakers to ensure that this new law is effectively implemented and paves the way to new payment models that foster high-quality, value-based health care for all Americans with cancer.”

Link to ASCO's press release: http://bit.ly/1aUigEC

Related Videos
Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program
Sandra Cuellar, PharmD
dr carol regueiro
dr carol regueiro
dr carol regueiro
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Screenshot of an interview with James Chambers, PhD
Corey McEwen, PharmD, MS
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo